198 related articles for article (PubMed ID: 38640253)
21. [The modulatory activity of T cell immunoglobulin and mucin domain-containing protein 3 on T lymphocytes in patients with chronic heart failure].
Yu HW; Dong YY; Dang YH
Zhonghua Yi Xue Za Zhi; 2020 May; 100(17):1315-1319. PubMed ID: 32375439
[No Abstract] [Full Text] [Related]
22. TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.
Gao X; Zhu Y; Li G; Huang H; Zhang G; Wang F; Sun J; Yang Q; Zhang X; Lu B
PLoS One; 2012; 7(2):e30676. PubMed ID: 22363469
[TBL] [Abstract][Full Text] [Related]
23. Id2 epigenetically controls CD8
Li Y; Han M; Wei H; Huang W; Chen Z; Zhang T; Qian M; Jing L; Nan G; Sun X; Dai S; Wang K; Jiang J; Zhu P; Chen L
Cell Mol Immunol; 2024 Mar; 21(3):292-308. PubMed ID: 38287103
[TBL] [Abstract][Full Text] [Related]
24. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.
Nagahara K; Arikawa T; Oomizu S; Kontani K; Nobumoto A; Tateno H; Watanabe K; Niki T; Katoh S; Miyake M; Nagahata S; Hirabayashi J; Kuchroo VK; Yamauchi A; Hirashima M
J Immunol; 2008 Dec; 181(11):7660-9. PubMed ID: 19017954
[TBL] [Abstract][Full Text] [Related]
25. Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity.
Minnie SA; Waltner OG; Ensbey KS; Nemychenkov NS; Schmidt CR; Bhise SS; Legg SRW; Campoy G; Samson LD; Kuns RD; Zhou T; Huck JD; Vuckovic S; Zamora D; Yeh A; Spencer A; Koyama M; Markey KA; Lane SW; Boeckh M; Ring AM; Furlan SN; Hill GR
Sci Immunol; 2022 Oct; 7(76):eabo3420. PubMed ID: 36240285
[TBL] [Abstract][Full Text] [Related]
26. Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3
Zhang T; Ren T; Song Z; Zhao J; Jiao L; Zhang Z; He J; Liu X; Qiu L; Li L; Zhou S; Meng B; Zhai Q; Ren X; Qian Z; Wang X; Zhang H
J Immunol Res; 2020; 2020():6968595. PubMed ID: 33178839
[TBL] [Abstract][Full Text] [Related]
27. Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
[TBL] [Abstract][Full Text] [Related]
28. TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.
Cianciotti BC; Magnani ZI; Ugolini A; Camisa B; Merelli I; Vavassori V; Potenza A; Imparato A; Manfredi F; Abbati D; Perani L; Spinelli A; Shifrut E; Ciceri F; Vago L; Di Micco R; Naldini L; Genovese P; Ruggiero E; Bonini C
Front Immunol; 2024; 15():1315283. PubMed ID: 38510235
[TBL] [Abstract][Full Text] [Related]
29. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
30. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
31. The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms.
Shibamiya A; Miyamoto-Nagai Y; Koide S; Oshima M; Rizq O; Aoyama K; Nakajima-Takagi Y; Kato R; Kayamori K; Isshiki Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Takeda Y; Koyama-Nasu R; Chiba T; Honda H; Yokote K; Iwama A; Sakaida E; Mimura N
Cancer Immunol Immunother; 2023 Aug; 72(8):2635-2648. PubMed ID: 37069353
[TBL] [Abstract][Full Text] [Related]
32. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
33. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models.
Ma S; Tian Y; Peng J; Chen C; Peng X; Zhao F; Li Z; Li M; Zhao F; Sheng X; Zong R; Li Y; Zhang J; Yu M; Zhu Q; Tian X; Li Y; Neckenig MR; Liu H; Zhan P; Yue X; Wu Z; Gao L; Liang X; Liu X; Li C; Ma C
Sci Transl Med; 2023 Nov; 15(722):eadg6752. PubMed ID: 37967204
[TBL] [Abstract][Full Text] [Related]
34. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
[TBL] [Abstract][Full Text] [Related]
35. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma.
Grube M; Moritz S; Obermann EC; Rezvani K; Mackensen A; Andreesen R; Holler E
Clin Cancer Res; 2007 Feb; 13(3):1053-60. PubMed ID: 17289902
[TBL] [Abstract][Full Text] [Related]
36. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.
Li Z; Liu X; Guo R; Wang P
Tumour Biol; 2017 May; 39(5):1010428317698352. PubMed ID: 28475007
[TBL] [Abstract][Full Text] [Related]
37. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8
Gardner A; de Mingo Pulido Á; Hänggi K; Bazargan S; Onimus A; Kasprzak A; Conejo-Garcia JR; Rejniak KA; Ruffell B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34987021
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Fourcade J; Sun Z; Benallaoua M; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Kuchroo V; Zarour HM
J Exp Med; 2010 Sep; 207(10):2175-86. PubMed ID: 20819923
[TBL] [Abstract][Full Text] [Related]
39. IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation.
Lee J; Lee K; Bae H; Lee K; Lee S; Ma J; Jo K; Kim I; Jee B; Kang M; Im SJ
Front Immunol; 2023; 14():1117092. PubMed ID: 37409128
[TBL] [Abstract][Full Text] [Related]
40. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
